Clinical Trial

A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of SHR-3792 injection monotherapy for patients with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-26.
Status change: Not Yet Recruiting → Recruiting 2025-04-24
Trial Details
NCT Number NCT06907628
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 150 participants
Start Date 2025-04-02
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-04-25